Endovia Health Sciences (EDVA) Proxy filing summary

Executive summary

• Special meeting scheduled for December 7, 2026, at 10:00 a.m. ET by live webcast; record date October 30, 2026, with 11,672,554 total votes. The Board unanimously recommends FOR all five proposals.

• Proposals seek approval for convertible-security share issuance, expanded ELOC share sales, 800 million authorized common shares, a discretionary reverse split, and adjournment if needed.

Voting matters and shareholder proposals

• Proposal 1 seeks approval to issue up to 12,683,908 shares under Series D and a $576,271 convertible note, beyond the 19.99% Exchange Cap; issuance could significantly dilute existing holders.

• Proposal 2 seeks approval for an initial issuance of up to 20 million ELOC shares beyond the Exchange Cap; the amended facility provides up to $100 million additional commitment, bringing stated total commitments to $135 million.

• Proposal 3 seeks to raise authorized common shares to 800 million; Proposal 4 would permit a 1-for-2 to 1-for-49 reverse split at the Board’s selected ratio; Proposal 5 allows adjournment to solicit votes if needed.

• Each proposal requires a majority of votes cast; abstentions count as votes against. Proposals 1–4 are non-routine; Proposal 5 is routine for broker voting purposes.

Board of directors and corporate governance

• The Board may choose whether to implement the reverse split and its ratio, or abandon it; if approved, implementation must occur before the first anniversary of the special meeting.

• The special meeting is virtual-only, with online participation and voting; the Board cites expanded global stockholder access as a benefit of the format.